Phase II Study of an Androgen Receptor Pathway Inhibitor + Atezolizumab + Gonadotropin-Releasing Hormone Analog and Stereotactic Body Radiotherapy in Hormone-Sensitive Metastatic Prostate Cancer
Metastatic androgen pathway modulation–sensitive (mAPMS) prostate cancer is generally immunologically cold. Emerging data suggest radiotherapy and androgen-deprivation therapy (ADT) augment the antitumor immune response to immune checkpoint blockade. We evaluated the efficacy and safety of atezolizumab combined wit...